Anil Gulati

Dr. Gulati is leading clinical development and the commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock. He has 54 issued patents. He is Professor Emeritus at Midwestern University and is recipient of Paul R Dawson Biotechnology Award 2014 and Littlejohn Award 2014. Dr. Gulati is a United States Fulbright Scholar 2008-2009 and winner of International Ranbaxy Research Award 2007. Dr. Gulati was the Scientific Reviewer, United States Defense Medical Research and Development Program, Combat Casualty Care Research Program 2016 and 2017.